Literature DB >> 9294699

Evaluation of Haemophilus influenzae isolates with elevated MICs to amoxicillin/clavulanic acid.

M R Jacobs1, S Bajaksouzian.   

Abstract

A 1994 to 1995 national Haemophilus influenzae surveillance study of 1910 strains showed that 13 strains (0.7%) were resistant to amoxicillin/clavulanic acid (MIC, > or = 8/4 micrograms/ml). These and other selected strains were investigated further in this study. Susceptibility of the surveillance study strains was determined with the commercial microdilution trays used in the original study and in triplicate with reference broth microdilution trays prepared by the investigators, as well as by Etest and disk diffusion. Amoxicillin/clavulanic acid resistance was confirmed for only one of the surveillance study strains. This strain produced double zones of growth with Etest and disk-diffusion methods, with the double zone containing spheroplasts. When the amoxicillin/clavulanic acid MICs of all beta-lactamase positive strains were compared, MIC results obtained with surveillance study trays and the Etest were one to two dilutions higher than MICs obtained with reference trays. The distribution and modal amoxicillin/clavulanic acid MICs of beta-lactamase-positive and -negative strains was essentially the same for a comparison group of strains using reference trays, in contrast to a fourfold higher modal MIC for beta-lactamase-positive strains using surveillance study reagents and strains. These differences in MICs could be attributed to variations in inoculum, the presence of spheroplasts, and/or a difference in potency of amoxicillin and/or clavulanic acid in the tray and Etest reagents used. Methods for assessing the adequacy of the clavulanic acid content are not adequate, amoxicillin control values and a beta-lactamase-positive H. influenzae control strain are required.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294699     DOI: 10.1016/s0732-8893(97)00008-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain.

Authors:  James A Karlowsky; Ian A Critchley; Renée S Blosser-Middleton; Elena A Karginova; Mark E Jones; Clyde Thornsberry; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 2.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

3.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Gengrong Lin; David Felmingham; Christine Dencer; Laura Koeth; Mendel E Singer; Caryn E Good
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

5.  Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae.

Authors:  Henri Dabernat; Catherine Delmas; Martine Seguy; Roseline Pelissier; Genevieve Faucon; Safia Bennamani; Christophe Pasquier
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

6.  Antimicrobial Susceptibility Survey of Invasive Haemophilus influenzae in the United States in 2016.

Authors:  Caelin C Potts; Lorraine D Rodriguez-Rivera; Adam C Retchless; Sean A Buono; Alexander T Chen; Henju Marjuki; Amy E Blain; Xin Wang
Journal:  Microbiol Spectr       Date:  2022-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.